Therapeutic Targeting of BET Bromodomain Proteins in Castration-resistant Prostate Cancer

Asangani IA, et al., doi: 10.1038/nature13229, Nature, 2014

In this report, the authors described the treatment and screening of prostate cancer and control cell lines and the identification of Bromodomain and extraterminal (BET) inhibitors that act on cell proliferation and knock down expression of specific cancer biomarkers suggesting new possibilities in alternative treatments for castration-resistant prostate cancer (CRPC). Binding studies were performed on the Octet RED system. Super Streptavidin biosensors were used.

Read More